Anatomy of a Shortage: Tracing the Recurring Supply Crises That Have Left American Azithromycin Patients Without Options
For most Americans, azithromycin represents something reassuringly routine — a short course of tablets prescribed for a respiratory infection, a strep throat, or a walking pneumonia diagnosis. It is one of the most dispensed antibiotics in the country, a fixture on pharmacy shelves for decades. That familiarity, however, has made the moments when those shelves go bare all the more disorienting. Across the past fifteen years, the United States has experienced multiple distinct episodes of azithromycin scarcity, each one exposing a different fracture point in the supply chain that delivers this medication from overseas manufacturing plants to American patients.
Understanding why these shortages happen — and why they keep happening — requires looking beyond any single news cycle and examining the structural forces that have made azithromycin supply chronically vulnerable.
The Manufacturing Geography Problem
The story of azithromycin shortages begins with a geographic reality that few patients consider when they hand over a prescription. The active pharmaceutical ingredient, or API, used to manufacture azithromycin in the United States is produced almost entirely outside the country. India and China together account for the overwhelming majority of global API production for this antibiotic, a concentration that creates systemic risk every time either nation experiences regulatory scrutiny, natural disaster, labor disruption, or geopolitical friction.
The U.S. Food and Drug Administration has issued warning letters and import alerts to foreign manufacturing facilities on multiple occasions over quality control deficiencies. When a major Indian generics manufacturer receives such an alert, the downstream effects ripple through American pharmacy networks within weeks. Distributors scramble to source product from alternative suppliers, but the pool of FDA-approved API sources is limited, and those alternative suppliers quickly face demand they are not equipped to absorb.
This is not a hypothetical vulnerability. It is a pattern that has materialized repeatedly, and the pharmaceutical industry's reliance on a narrow band of overseas production facilities has been cited by the FDA itself as a structural risk to American drug security.
The Pandemic Acceleration
No examination of azithromycin supply disruptions is complete without acknowledging the events of 2020. When early, widely publicized — and ultimately unsubstantiated — claims circulated about azithromycin as a potential COVID-19 treatment, demand for the antibiotic surged at a scale the supply chain was wholly unprepared to handle. Retail pharmacies reported unprecedented dispensing volumes. Hospitals placed bulk orders to stock formularies in anticipation of treating infected patients. Compounding pharmacies began receiving requests they lacked the raw materials to fulfill.
The result was a shortage that the American Society of Health-System Pharmacists formally designated as a drug shortage event — a classification that triggers specific reporting obligations and signals to clinicians that prescribing alternatives may be necessary. The azithromycin shortage of 2020 was not caused by manufacturing failure alone; it was demand-driven, accelerated by misinformation, and resolved only gradually as the clinical evidence failed to support the antibiotic's use against a viral pathogen.
What the pandemic episode revealed, however, was not simply that demand spikes are dangerous. It revealed that the buffer inventory maintained across the American pharmaceutical distribution system was insufficient to absorb even a few weeks of elevated demand without triggering visible scarcity at the pharmacy counter.
Regulatory Actions and Their Unintended Consequences
FDA enforcement activity, while necessary for patient safety, has contributed to shortage episodes in ways that are rarely discussed openly. When a manufacturing facility is placed on import alert or a product lot is recalled due to contamination or specification failure, the affected volume must be replaced. If the manufacturer in question holds a significant share of the U.S. market — which is common in a generic drug landscape characterized by consolidation — that replacement volume may simply not exist in the short term.
Several generic azithromycin manufacturers have faced FDA scrutiny over the years for issues ranging from inadequate stability testing to data integrity concerns at their overseas facilities. Each enforcement action, however justified on safety grounds, temporarily removes supply from a market that operates with thin margins and minimal redundancy.
The paradox is a difficult one for regulators: enforcing quality standards protects patients from substandard medication, but the enforcement itself can create access problems for patients who need the drug immediately.
Seasonal Demand Cycles and the Inventory Mismatch
Beyond acute disruption events, azithromycin supply is subject to predictable seasonal stress that the distribution system has historically managed imperfectly. Respiratory illness season in the United States — roughly October through March — drives a reliable increase in azithromycin prescriptions for community-acquired pneumonia, acute bacterial sinusitis, and other upper respiratory conditions. Wholesalers and pharmacy chains are aware of this cycle, yet the lean inventory practices that characterize modern pharmaceutical distribution leave little room for demand spikes that exceed seasonal forecasts.
A particularly severe influenza season, a regional outbreak of pertussis, or an unusual cluster of Mycoplasma pneumoniae infections can push demand beyond what distributors have positioned to meet. The result is regional scarcity — not a national shortage in the formal sense, but a localized experience of unavailability that is functionally identical for the patient standing at the pharmacy counter.
What Patients Can Reasonably Do
The structural forces driving azithromycin shortages are largely beyond individual patient control. Manufacturing geography, regulatory enforcement, and distribution economics are policy-level problems requiring policy-level solutions. That said, patients who depend on azithromycin for recurrent or chronic conditions can take practical steps to reduce their personal exposure to shortage risk.
Maintaining an open, ongoing conversation with a prescribing physician about therapeutic alternatives is perhaps the most important preparation available to any patient. Beta-lactam antibiotics, doxycycline, and other agents are clinically appropriate for many of the same indications treated with azithromycin, and understanding which alternatives are acceptable for a specific patient's medical history allows a provider to pivot quickly when azithromycin is unavailable.
Patients should also be aware that azithromycin shortages tend to be unevenly distributed across pharmacy networks. A large chain pharmacy in one ZIP code may be out of stock while an independent pharmacy across town has supply. Calling ahead before making a trip, and being willing to transfer a prescription to an in-stock location, can make the difference between a delayed treatment course and a timely one.
Finally, patients should resist the temptation to stockpile antibiotics during periods of availability. Hoarding behavior, however individually rational it may feel, worsens the shortage conditions that motivate it — and storing antibiotics improperly reduces their efficacy in ways that may not be apparent until the medication is actually needed.
A Systemic Problem Requiring Systemic Solutions
The recurring nature of azithromycin shortages in the United States is, at its core, a policy failure as much as a market failure. Legislative proposals to incentivize domestic API manufacturing, expand FDA's shortage early-warning capacity, and require minimum inventory buffers for essential generic medications have all been introduced in Congress with varying degrees of momentum. None has yet produced the structural change that would meaningfully reduce the frequency or severity of future shortages.
Until such changes materialize, American patients and the clinicians who serve them will continue to navigate a supply environment that is more fragile than the routine availability of azithromycin might suggest. Awareness of that fragility — and of the historical pattern that has produced it — is the first step toward managing it effectively.
